Home Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
 

Keywords :   


Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes

2016-06-11 17:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. & NEW YORK Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). Language: English Contact: Merck Media Contacts:Doris Li, 908-246-5701orKristen Drake, 908-334-4688orMerck Investor Contact:Justin Holko, 908-740-1879orPfizer Media Contact:Steve Danehy, 212-733-1538orPfizer Investor Contact:Ryan Crowe, 212-733-8160 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: PFE Exchange: NYSE read more

Tags: with type showing met

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11NI rise hits workers harder than employers, says OBR
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 8
05.11Tropical Storm Rafael Public Advisory Number 8
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 8
05.11Lenzing Expands Nonwovens Range
05.11Netflix Europe offices raided in tax fraud probe
More »